Standout Papers

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-U... 2023 2026 202496
  1. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up (2023)
    Thomas Powles, Se Hoon Park et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

Advances in diagnosis and treatment of bladder cancer
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
14 intermediate papers

Works of Anders Ullén being referenced

Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
2021
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
2020
and 5 more

Author Peers

Author Last Decade Papers Cites
Anders Ullén 593 379 429 382 86 1.2k
Bishoy M. Faltas 704 491 460 464 73 1.4k
Vadim S. Koshkin 624 462 520 329 111 1.2k
Tony Elliott 520 720 495 320 58 1.5k
Darrel Drachenberg 661 747 366 425 99 1.5k
Daniel Kedar 541 387 330 411 52 1.3k
Thorsten Ecke 660 402 284 408 105 1.3k
Joerg Hennenlotter 438 441 192 367 72 1.1k
Steffen Rausch 463 545 288 485 120 1.3k
Junya Furukawa 353 581 325 355 112 1.2k
Omar Hameed 347 637 578 437 81 1.7k

All Works

Loading papers...

Rankless by CCL
2026